Wenisch C, Linnau K F, Looaresuwan S, Rumpold H
Department of Internal Medicine I, University Hospital of Vienna, Austria.
J Infect Dis. 1999 Mar;179(3):747-50. doi: 10.1086/314630.
Plasma levels of interleukin (IL)-6, soluble IL-6 receptor, soluble gp130, leukemia inhibitory factor (LIF), and ciliary neutrophic factor (CNTF) were analyzed in 32 patients with severe malaria. Ten had renal failure, 8 had cerebral malaria, and 14 had other causes of severity. Before treatment, the IL-6 and soluble IL-6 receptor plasma levels were significantly higher in persons with cerebral malaria or renal failure than in other groups (P<.01 for both). After initiation of therapy, IL-6 levels dropped within 24 h, but soluble IL-6 receptor levels increased. CNTF levels were significantly reduced in persons with cerebral malaria or renal failure but normalized within 24 h. Plasma concentrations of gp130 and LIF did not differ between the malaria groups or normal controls. Excessive levels of IL-6 could be controlled by a subsequent shedding of the soluble IL-6 receptor, and low-level CNTF expression could contribute to or even result from cerebral malaria or renal failure.
对32例重症疟疾患者的血浆白细胞介素(IL)-6、可溶性IL-6受体、可溶性gp130、白血病抑制因子(LIF)和睫状神经营养因子(CNTF)水平进行了分析。其中10例有肾衰竭,8例有脑型疟疾,14例有其他导致病情严重的原因。治疗前,脑型疟疾或肾衰竭患者的IL-6和可溶性IL-6受体血浆水平显著高于其他组(两者均P<0.01)。开始治疗后,IL-6水平在24小时内下降,但可溶性IL-6受体水平升高。脑型疟疾或肾衰竭患者的CNTF水平显著降低,但在24小时内恢复正常。疟疾组与正常对照组之间的gp130和LIF血浆浓度无差异。过量的IL-6可通过随后可溶性IL-6受体的释放得到控制,低水平的CNTF表达可能促成脑型疟疾或肾衰竭,甚至可能是其结果。